Regenerative Medicine and Advanced Therapies is a discipline critical to research translation, with the market value for regenerative therapies projected to reach $38 billion in the US alone by 2024 and NUI Galway is at the global forefront of pioneering advances in Regenerative Medicine and Advanced Therapies. 

The Regenerative Medicine Institute (REMEDI) is a world-class biomedical research centre focusing on gene therapy and stem cell research. This centre is a partnership involving scientists, clinicians, and engineers in academic centres and industry. Researchers at REMEDI work together to combine the technologies of gene therapy and adult stem cell therapy with the aim of regeneration and repair of tissues.

Funded initially under a SFI Centre for Science Engineering and Technology, REMEDI has been closely affiliated with CÚRAM since 2016, bringing additional strength in biomaterials and device design and public engagement related to advanced therapies.

Major research strands within REMEDI exemplify the potential to lead and partner on ambitious, cross-theme health challenge-focussed projects.

REMEDI has built an internationally recognised track record of excellence in basic, preclinical, clinical/translational and socioeconomic research in the areas of stem cell science, regenerative medicine, immunology and cell therapy manufacturing.

A key distinction, the establishment of Ireland’s first GMP-grade therapeutic cell manufacturing facility, the Centre for Cell Manufacturing Ireland (CCMI), has enabled the development of an early phase clinical trial infrastructure for cell therapies, a successful cell therapy spin-out company (Orbsen Therapeutics Ltd.) and internationally-networked clinical translational programmes in diabetology, respiratory medicine/critical care, cardiology, nephrology, bone and joint disease and cancer.

REMEDI PIs have coordinated and partnered in >10 EU collaborative projects (approximately €60 million of funding) related to regenerative medicine and advanced therapies, four of which have led to regulator-approved early phase clinical trials. Very recently, the capacity for clinical-grade cell therapy manufacturing has underpinned the funding of large, industry-partnered grants to NUI Galway in the areas of immune cell therapies for cancer and aerosolisation of advanced therapies for COVID19 acute lung injury. REMEDI faculty also coordinate distinctive taught Masters programmes in Regenerative Medicine and Cellular Manufacturing; are active supervisors for the Wellcome Trust-funded Irish Clinical Academic Training (ICAT) Programme and direct NUI Galway’s Flow Cytometry Core Facility.